Clinical Trials Browser

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT07295821 2026-04-08

NSCLC

Phase 2 Recruiting

60 enrolled

Thoracic

Lung Neoplasms

NCT05261399 2026-04-06

SAFFRON

Phase 3 Active not recruiting

345 enrolled

Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

NCT05629234 2026-04-06

ROSY-T

Phase 3 Active not recruiting

37 enrolled

Tumor-Agnostic

Neoplasms

NCT05785741 2026-04-06

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

1,000 enrolled

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03040973 2026-04-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Phase 2 Active not recruiting

29 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04665206 2026-04-02

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Phase 1/2 Recruiting

434 enrolled

Other solid neoplasmThoracic

Mesothelioma

NCT02511106 2026-03-30

ADAURA

Phase 3 Active not recruiting

682 enrolled 20 charts 2 FDA

Thoracic

Stage IB-IIIA Non-small Cell Lung Carcinoma

Clinical Trials

MARIPOSA

FLAURA

COMPEL

AURA

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

LuCa-MERIT-1

NSCLC

SAFFRON

ROSY-T

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

ADAURA